Zika virus-IN-1

Zika virus-IN-1 is an inhibitor of Zika virus (EC50: 1.56 μM).

DENV-2/ZIKV-IN-1 (Compd 16a) is a dual inhibitor of dengue virus (DENV) and Zika virus (ZIKV), exhibiting EC50 values of 1.4 μM and 2.4 μM, respectively.

p-nitro-Pifithrin-α is a cell-permeable analog of pifithrin-α, a potent p53 inhibitor. It suppresses p53-mediated TGF-β1 expression in HK-2 cells and inhibits the activation of caspase-3 by Zika virus (ZIKV) strains. Moreover, p-nitro-Pifithrin-α attenuates steatosis and liver injury in mice subjected to a high-fat diet, mitigating the effects of non-alcoholic fatty liver disease [1] [2] [3] [4].

Zika virus-IN-3 (Compd 7) is a Zika virus inhibitor with an EC50 of 3.4 μM [1].

ZIKV-IN-1 is a potent inhibitor of Zika virus (EC50: 2.8 μM, EC90: 6.8 μM) with anti-ZIKV effects and low cytotoxicity, showing high affinity for the RdRp domain of ZIKV.

CYP2C19-IN-1 is a potent, non-genotoxic, non-hepatotoxic inhibitor of CYP2C19. CYP2C19-IN-1 inhibits RNA-dependent RNA polymerase (RdRP) (Ki: 6.16 μM) and can be used to study Zika virus (ZIKV) infection.

CYP2C9/CYP2C19-IN-1 is a potent inhibitor of CYP2C9/CYP2C19 without liver toxicity or genotoxicity and can be used to study Zika virus (ZIKV) infection.

CLR01 is a molecular tweezer. CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy. CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly in vitro and in the G93A-SOD1 mouse model of ALS. CLR01 inhibits Ebola and Zika virus infection. CLR01 Stabilizes a Disordered Protein-Protein Interface. CLR01, Modulates Aggregation of the Mutant p53 DNA Binding Domain and Inhibits Its Toxicity.

NSC 288387, a pan-flavivirus MTase inhibitor, binds to the SAM-binding pocket and effectively inhibits Zika virus (ZIKV) with an IC50 of 0.2 μM, also preventing viral replication in cell culture [1].

Wulfenioidin H (Compound 5), a diterpenoid, demonstrates anti-Zika virus (ZIKV) activity by inhibiting the expression of the ZIKV envelope (E) protein, resulting in an effective concentration \( EC_{50} \) value of 8.50 μM [1].

ZIKV-IN-6 (compound 22) is a direct inhibitor of the Zika virus (ZIKV) that binds to its RNA-dependent RNA polymerase (RdRp), obstructing viral RNA synthesis mediated by the ZIKV NS5 protein. The compound exhibits low cytotoxicity (CC50 >50 μM) and mitigates excessive inflammatory response and pyroptosis [1].

Compound 11, also known as NS2B-NS3pro-IN-2, functions as an inhibitor of the Zika Virus NS2B-NS3 protease and exhibits antiviral properties at a concentration of 50 μM [1].

NS2B-NS3pro-IN-1, a potent Zika Virus NS2B-NS3 protease inhibitor, exhibits an EC50 of 50 μM and is significant in the ZIKV replication cycle [1].

ASN 07115873 is a small-molecule compound reported in screening studies to exhibit inhibitory activity against Zika virus infection, with a reported IC50 of approximately 189.2 pM. ASN 07115873 is used in antiviral mechanism research and drug screening studies.

NS2B/NS3-IN-8, also known as compound MH1, is an inhibitor of the Zika virus NS2B-NS3 protease [1].